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Graphical abstract 
 
 
Abstract 
 
This is a mathematical study about tumor growth from a different perspective, with the aim 
of predicting and/or controlling the disease. The focus is on the effect and interaction of 
tumor cell with immune and drug. This paper presents a mathematical model of immune 
response and a cycle phase specific drug using a system of ordinary differential equations.  
Stability analysis is used to produce stability regions for various values of certain parameters 
during mitosis. The stability region of the graph shows that the curve splits the tumor decay 
and growth regions in the absence of immune response. However, when immune response 
is present, the tumor growth region is decreased. When drugs are considered in the system, 
the stability region remains unchanged as the system with the presence of immune 
response but the population of tumor cells at interphase and metaphase is reduced with 
percentage differences of 1.27 and 1.53 respectively. The combination of immunity and 
drug to fight cancer provides a better method to reduce tumor population compared to 
immunity alone. 
 
Keywords: Tumor growth, immune response, cycle phase specific drug, cell cycle, stability 
region 
 
Abstrak 
 
Kajian ini adalah berkenaan dengan pertumbuhan tumor daripada sudut perspektif yang 
berbeza, bertujuan untuk meramal atau mengawal penyakit tersebut. Fokus perspektif 
tersebut adalah kesan dan interaksi antara sel tumor dengan sistem imunisasi dan ubat. 
Kajian ini menerangkan sistem persamaan terbitan yang melibatkan pertumbuhan tumor 
bersama tindak balas imunisasi dan ubat yang bertindak mengikut fasa spesifik dalam 
kitaran sel. Kaedah analisis kestabilan digunakan untuk menghasilkan kawasan kestabilan 
bagi nilai-nilai parameter tertentu dalam fasa mitosis. Kawasan kestabilan untuk 
ketidakhadiran tindak balas imunisasi menunjukkan kawasan pertumbuhan tumor dan 
kawasan pereputan tumor dipisahkan oleh garis lengkuk. Dengan kehadiran tindak balas 
imunisasi, kawasan pertumbuhan tumor didapati berkurang. Apabila ubat untuk kitaran 
spesifik diambil kira dalam sistem, kawasan kestabilan tidak mengalami sebarang 
perubahan tetapi pertumbuhan sel-sel tumor pada kedua-dua fasa berkurang dengan 
perbezaan peratus masing-masing 1.27 dan 1.53. Ini menunjukkan bahawan gabungan 
antara imunisasi dan ubat adalah cara yang lebih baik untuk mengurangkan populasi sel 
tumor berbanding dengan hanya bergantung pada tindak balas imunisasi sahaja. 
 
Kata kunci: Pertumbuhan tumor, tindak balas imunisasi, ubat untuk kitaran fasa spesifik, 
kitaran sel, kawasan kestabilan 
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1.0  INTRODUCTION 
 
Every year more than 8.2 million people die from 
cancer worldwide [1]. World Health organization [2] 
reports that the majority of death caused by cancer 
occurs in countries that are economically well 
developed. This scenario forces scientists all over the 
world to develop theory and practical strategies to 
address the threat from cancer. On the whole, most 
researchers focused on particular issues since the 
interaction between tumor cells and other type of 
cells are very complex. Immune system plays an 
important role in human body to fight tumor. However 
there are limits for ability of immune system due to 
unpredictable tumor behaviour [3]. In medical 
treatment, chemotherapy offers a powerful 
mechanism among other tools to kill cancer cell, but 
it also kill the normal cells [4, 5, 6].  
The problem of modelling tumor growth is a vast 
study by researchers, with each focussing on different 
aspects on cancer development [7]. This includes the 
importance of the immune systems in fighting tumor 
that has been summarized by Adam and Bellomo [8]. 
Kuznetsov et al. [9] proposed an ordinary differential 
equation model of the cytotoxic T lymphocyte (CTL) 
response with population of tumor cells. They found 
that CTL and tumor cells competed like “predator-
prey” interaction in which CTL in the role of predator 
while tumor cell act as prey. Adam [10] then 
formulated the cell populations of a solid tumor and 
reactive lymphocyte and found that if the immune 
system is stimulated, the survival chance for tumor 
increases. In addition, whether growth rate and death 
rate increase or decrease, this condition will probably 
lead to an uncontrolled tumor growth. De Pillis et al. 
[11] proceeded to develop and analyze a 
mathematical model in order to understand the 
dynamics between tumor and immune system. The 
model concluded out that the combination effect of 
natural killer (NK) and CD8+ T cells could eliminate 
larger tumors compared to the effect of individual 
immune cell. This is due to the depletion of NK cells 
having different impact to CD8+ T cells. 
Chemotherapy is usually the first treatment for 
cancer [4, 5, 6, 12, 13]. Pastorino et al. [14] reported 
that chemotherapy treatments are in the process of 
improvement for better distribution mechanism that 
will reduce the toxicity of anticancer drugs. Besides, 
most of the drug used are cycle phase specific drugs 
such as vincristine and paclitaxel which interfere with 
certain phases in cell cycle [15]. It may prevent the 
cell from continuing the cycle, causing the 
proliferation to be stopped. Immune system then 
target and kill the cancerous cell by their natural 
mechanism. By taking this advantage, it will minimized 
the loss of normal cells. The use of cycle phase specific 
drugs have been included in the model proposed by 
Villasana M. and Radunskaya [16]. However, they did 
not present results of analysis and numerical 
computation had not been shwn in their paper. 
A different approach was adopted by Villasana M. 
and Radunskaya [16]. They presented a system of 
differential equations without considering any delay 
terms. Numerical results were done as a contribution 
to investigate the stability of the presented model. The 
model takes the form of ordinary differential equation 
(ODE) which includes tumor cell population during 
interphase, tumor population during metaphase, 
immune response and cycle phase with specific 
drugs. Three different systems were discussed by 
analysing its stability and numerical examples using 
Fourth Order Runge Kutta Method. 
 
 
2.0  METHODOLOGY 
 
The tumor growth model considered in this paper is a 
system of first order differential equations with nth 
dimensional system. 
 
𝑑𝑥1
𝑑𝑡
= 𝑓1(𝑥1, 𝑥2, … , 𝑥𝑛) 
𝑑𝑥2
𝑑𝑡
= 𝑓2(𝑥1, 𝑥2, … , 𝑥𝑛) 
⋮ 
𝑑𝑥𝑛
𝑑𝑡
= 𝑓𝑛(𝑥1, 𝑥2, … , 𝑥𝑛) 
(1) 
 
where 𝑥1, 𝑥2, … , 𝑥𝑛 are the variables, 𝑓1 , 𝑓2, … , 𝑓𝑛 can be 
linear or nonlinear functions and the right hand side of 
the ODEs may depend only on the independent 
variable 𝑡 [17]. The first step is to find the steady state 
solution of the system 
 
2.1  Steady State Solution 
 
A steady state or equilibrium point, ?̅? = (?̅?1, ?̅?2, … , ?̅?𝑛) is 
a situation in which the system does not appear to 
undergo any change [18]. To find the steady state of 
a system, set the derivatives equal to zero: 
 
𝑑𝑥1
𝑑𝑡
= 0 
𝑑𝑥2
𝑑𝑡
= 0 
⋮ 
𝑑𝑥𝑛
𝑑𝑡
= 0 
(2) 
 
There may exist one or several steady state points. 
 
2.2  Stability of Steady State 
 
The stability of steady state can be investigated by 
using Routh-Hurwitz condition/criteria [18, 19, 20].  
System (1) is linearized using Jacobian Matrix 
 
𝑱(?̅?1, ?̅?2, … , ?̅?𝑛) =
(
 
 
𝜕𝑓1
𝜕𝑥1
⋯
𝜕𝑓1
𝜕𝑥𝑛
⋮ ⋱ ⋮
𝜕𝑓𝑛
𝜕𝑥1
⋯
𝜕𝑓𝑛
𝜕𝑥𝑛)
 
 
 (3) 
 
The next step is to find the eigenvalues, 𝜆 satisfying 
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det(𝑱 − 𝜆𝑰) = 𝟎 (4) 
 
This will yield a characteristic equation of the form 
 
𝜆𝑛 + 𝑝1𝜆
𝑛−1 + 𝑝2𝜆
𝑛−2 +⋯+ 𝑝𝑛 = 0 (5) 
 
where 𝑝𝑖′𝑠 will be functions of the elements of the 𝑛 ×
𝑛 matrix.  
 
 
The Hurwitz matrix is defined as follows: 
 
𝑯𝟏 = (𝑝1), 
𝑯𝟐 = (
𝑝1 1
𝑝3 𝑝2
), 
𝑯𝟑 = (
𝑝1 1 0
𝑝3 𝑝2 𝑝1
𝑝5 𝑝4 𝑝3
),… 
𝑯𝒋 =
(
 
 
𝑝1
𝑝3
𝑝5
1
𝑝2
𝑝4
  0    0
  𝑝1   … 0
  𝑝3  0
…    ⋱  
𝑝2𝑗−1 𝑝2𝑗−2 𝑝2𝑗−3 … 𝑝𝑗)
 
 
,… 
𝑯𝒏 =
(
 
 
𝑝1
𝑝3
𝑝5
1
𝑝2
𝑝4
  0    0
  𝑝1   … 0
  𝑝3  0
…    ⋱  
0 0     0     … 𝑝𝑛)
 
 
 
 
where the (𝑙,𝑚) element in the matrix 𝐻𝑗 is 
 
           𝑝2𝑙−𝑚            for 0 < 2𝑙 −𝑚 < 𝑘 
              1                for 2𝑙 = 𝑚 
              2                for 2𝑙 < 𝑚 or 2𝑙 > 𝑘 + 𝑚 
 
 
 
 
 
 
 
 
(6) 
 
Hence, all eigenvalues have negative real parts 
(steady state stable) if and only if the determinants of 
the Hurwitz matrix are positive: 
 
det(𝑯𝒋) > 0, (𝑗 = 1,2,… , 𝑘) (7) 
 
2.3  Numerical Method 
 
Runge Kutta (RK4) method is applied to present 
several graphical results using MATLAB software. Tay et 
al. [21] considered an initial value problem of the first 
order differential equation given below: 
 
𝑑𝑥
𝑑𝑡
= 𝐹(𝑡, 𝑥, 𝑦) 
𝑑𝑦
𝑑𝑡
= 𝐺(𝑡, 𝑥, 𝑦) 
(8) 
 
with 𝑥(𝑡0) = 𝑥0, 𝑦(𝑡0) = 𝑦0 and 𝑡0 ≤ 𝑡 ≤ 𝑡𝑛. This problem 
is a system of ODEs, which consists of a single pair of 
ordinary differential equations. The solution domain is 
discretized such that 𝑡0, 𝑡1 = 𝑡0 + ℎ, 𝑡𝑛 = 𝑡0 + 𝑛ℎ, where 
ℎ is the step size of 𝑡. The solution that is obtained by 
the RK4 method is given as 
 
𝑥𝑖+1 = 𝑥𝑖 +
1
6
(𝑓1 + 2𝑓2 + 2𝑓3 + 𝑓4), 
𝑦𝑖+1 = 𝑦𝑖 +
1
6
(𝑔1 + 2𝑔2 + 2𝑔3 + 𝑔4), 
(9) 
 
where  
 
𝑓1 = ℎ𝑓(𝑡𝑖 , 𝑥𝑖, 𝑦𝑖) 
𝑓2 = ℎ𝑓 (𝑡𝑖 +
ℎ
2
, 𝑥𝑖 +
𝑓1
2
, 𝑦𝑖 +
𝑔1
2
) 
𝑓3 = ℎ𝑓 (𝑡𝑖 +
ℎ
2
, 𝑥𝑖 +
𝑓2
2
, 𝑦𝑖 +
𝑔2
2
) 
𝑓4 = ℎ𝑓(𝑡𝑖 + ℎ, 𝑥𝑖 + 𝑓3, 𝑦𝑖 + 𝑔3) 
𝑔1 = ℎ𝑔(𝑡𝑖 , 𝑥𝑖 , 𝑦𝑖) 
𝑔2 = ℎ𝑔 (𝑡𝑖 +
ℎ
2
, 𝑥𝑖 +
𝑓1
2
, 𝑦𝑖 +
𝑔1
2
) 
𝑔3 = ℎ𝑔 (𝑡𝑖 +
ℎ
2
, 𝑥𝑖 +
𝑓2
2
, 𝑦𝑖 +
𝑔2
2
) 
𝑔4 = ℎ𝑔(𝑡𝑖 + ℎ, 𝑥𝑖 + 𝑓3, 𝑦𝑖 + 𝑔3) 
 
 
 
3.0  RESULTS AND DISCUSSION 
 
The system considers three population which are 
population of tumor cells during interphase (G1 + S + 
G2) denoted by 𝑇𝐼 , population of tumor cells during 
mitosis denoted by 𝑇𝑀 and population of immune 
response denoted by 𝐼. In this research, Cytotoxic T 
Lymphocytes (CTL) is assume to be main 
representative of the immune system in fight cancer. 
A certain amount of cycle phase specific drug is 
included to analyze the effect on the system. The 
model takes form 
 
     
𝑑𝑇𝐼
𝑑𝑡
= 2𝑎4𝑇𝑀 − (𝑐1𝐼 + 𝑑2)𝑇𝐼 − 𝑎1𝑇𝐼 
(10) 
    
𝑑𝑇𝑀
𝑑𝑡
= 𝑎1𝑇𝐼 − 𝑑3𝑇𝑀 − 𝑎4𝑇𝑀 − 𝑐3𝑇𝑀𝐼
− 𝑘1(−𝑒
−𝑘2𝑢)𝑇𝑀 
𝑑𝐼
𝑑𝑡
= 𝑘 +
𝜌𝐼(𝑇𝐼 + 𝑇𝑀)
𝑛
𝛼 + (𝑇𝐼 + 𝑇𝑀)𝑛
− 𝑐2𝐼𝑇𝐼 − 𝑐4𝑇𝑀𝐼 − 𝑑1𝐼
− 𝑘3(1 − 𝑒
−𝑘4𝑢)𝐼 
    
𝑑𝑢
𝑑𝑡
= −𝛾𝑢 
 
where parameter 𝑎1 and 𝑎4 represent the rates of cell 
cyle and rates of cell reproduction respectively.  
Besides, the proportion for cell deaths are represent by 
the term 𝑑2𝑇𝐼, 𝑑3𝑇𝑀 and 𝑑1𝐼. Note that the term 2𝑎4𝑇𝑀 
present in the equation because in fact, one parent 
cell will split into two new daughter cells during mitosis. 
The parameter 𝑐𝑖 then represent the losses of immune 
cell or tumor cell during the event of an encounter for 
both cell. Due to the presence of tumor, the growth 
for immune population is assumed to be nonlinear 
which indicated by the term 
𝜌𝐼(𝑇𝐼+𝑇𝑀)
𝑛
𝛼+(𝑇𝐼+𝑇𝑀)
𝑛. Another 
parameter which are 𝜌, 𝛼, and 𝑛 in the equations are 
influence by the type of tumor itself together with the 
healthiness of patient’s immune system. 
The impact of drug towards tumor population in 
mitosis and immune are modeled by the killing terms 
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𝑘1(1 − 𝑒
−𝑘2𝑢)𝑇𝑀 and 𝑘3(1 − 𝑒
−𝑘4𝑢)𝐼 respectively. Since 
the drug is decay over time, it assumed to be 
exponential while parameter 𝛾 acts as both 
elimination and absorption effects. This paper 
highlights only an application of single drug dose 
treatment, otherwise it is beyond the scope of this 
paper. 
It is important to know that the parameter values 
are vary for any model presented since patients have 
different types of tumor. Thus, it is allowed to vary the 
parameter values in order to understand better of 
tumor problem. This research will used the non 
dimensionalized parameter that have been set by 
Villasana and Ochoa [21]. 
 
𝑎1 = 0.98; 𝑎4 = 0.8; 𝑑1 = 0.29; 𝑑2 = 0.11; 𝑑3 = 0.4 
𝑐1 = 𝑐3 = 0.9;  𝑐2 = 𝑐4 = 0.085;  𝑘 = 0.029 
𝑘1 = 0.47;  𝑘2 = 0.57;  𝑘3 = 0.49; 𝑘4 = 0.061 
𝛼 = 0.2;  𝜌 = 0.1;  𝑛 = 3;  𝛾 = 0.85 
 
The analysis is divide into three cases which are 
tumor system without immune response, tumor system 
with the presence of immune response and tumor 
system with single drug. The behavior of these system 
are depended on fixed point and its stability. 
Numerical examples for certain chosen parameters in 
stability region are then computed using Fourth Order 
Runge Kutta Method. 
 
3.1  Tumor System without Immune Response 
 
Consider a system of ordinary differential equations: 
 
𝑑𝑇𝐼
𝑑𝑡
= 2𝑎4𝑇𝑀 − (𝑑2 + 𝑎1)𝑇𝐼 
𝑑𝑇𝑀
𝑑𝑡
= 𝑎1𝑇𝐼 − 𝑑3𝑇𝑀 − 𝑎4𝑇𝑀 
  (11) 
 
The auxiliary equation at tumor free point (𝑇𝐼 , 𝑇𝑀) =
(0,0) is 
 
𝜆2 + (𝑎1 + 𝑑 + 𝑑2)𝜆 + 𝑑(𝑎1 + 𝑑2) − 2𝑎1𝑎4 = 0 (12) 
                                                        𝜆2 + 𝑝1𝜆 + 𝑝2 = 0 (13) 
 
where 
 
∴  𝑝1 = 𝑎1 + 𝑑 + 𝑑2 (14) 
                     𝑝2 =  𝑑(𝑎1 + 𝑑2) − 2𝑎1𝑎4 (15) 
 
The value of 𝑝1 from Eq. (14) is always positive [15, 16, 
22]. The value of 𝑝2 can be negative or positive. 
According to the Routh-Hurwitz stability criteria, the 
tumor free point will be stable if 𝑝1 > 0 and  𝑝2 > 0. 
Thus, the necessary condition for the tumor growth is 
given by Eq. (16). 
 
𝑑 <
2𝑎1𝑎4
𝑎1 + 𝑑2
 (16) 
 
 
 
Figure 1 Stability region for the case without immune 
response when 𝑎4 = 0.8 and 𝑑2 = 0.11 
 
 
 
Figure 2 Numerical example for stable fixed point (0,0) when 
𝑎1 = 1 and 𝑑 = 1.9 with initial condition 𝑇𝐼(0) = 1.3 and 𝑇𝑀(0) =
1.2 
 
 
 
Figure 3 Numerical example for unstable fixed point 
(0,0) when 𝑎1 = 1 and 𝑑 = 0.8 with initial condition 𝑇𝐼(0) = 1.3 
and 𝑇𝑀(0) = 1.2 
 
 
II 
I 
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From Figure 1, the region for tumor growth where (0,0) 
unstable is given by I and the region for tumor decay 
where (0,0) stable is given by the complement II. The 
values were chosen from different regions to observe 
the solution of the system as presented in Figure 2 and 
Figure 3. 
 
3.2 Tumor System with the presence of Immune 
Response 
 
In this case, the effect of immune response is added 
to the model. The system of equations now becomes 
 
     
𝑑𝑇𝐼
𝑑𝑡
= 2𝑎4𝑇𝑀 − (𝑐1𝐼 + 𝑑2)𝑇𝐼 − 𝑎1𝑇𝐼 
(17)    
𝑑𝑇𝑀
𝑑𝑡
= 𝑎1𝑇𝐼 − 𝑑3𝑇𝑀 − 𝑎4𝑇𝑀 − 𝑐3𝑇𝑀𝐼 
      
𝑑𝐼
𝑑𝑡
= 𝑘 +
𝜌𝐼(𝑇𝐼 + 𝑇𝑀)
𝑛
𝛼 + (𝑇𝐼 + 𝑇𝑀)𝑛
− 𝑐2𝐼𝑇𝐼 − 𝑐4𝑇𝑀𝐼 − 𝑑1𝐼 
 
One of the tumor free point is (𝑇𝐼 , 𝑇𝑀, 𝐼) = (0,0,
𝑘
𝑑1
) with 
zero tumor population. This is our starting point since it 
represents a tumor free condition. The factorization 
form of the auxiliary equation at this steady state yields 
Eq. (18). 
 
(−𝑑1 − 𝜆)[(−𝑐1𝑑1̅̅ ̅ − 𝑑2 − 𝑎1 − 𝜆)(−𝑑 − 𝑐3𝑑1̅̅ ̅
− 𝜆) − 2𝑎1𝑎4] = 0 
(18) 
 
where 𝑑1̅̅ ̅ =
𝑘
𝑑1
. Clearly, one of the eigenvalue is 𝜆 =
−𝑑1. The remaining eigenvalues are given as the 
solution to the auxiliary equation 
 
𝜆2 + [𝑎1 + 𝑑2 + (𝑐1 + 𝑐3)𝑑1̅̅ ̅ + 𝑑]𝜆
+ (𝑎1 + 𝑑2 + 𝑐1𝑑1̅̅ ̅)(𝑑
+ 𝑐3𝑑1̅̅ ̅) − 2𝑎1𝑎4 = 0 
(19) 
𝜆2 + 𝑝1
∗𝜆 + 𝑝2
∗ = 0 (20) 
 
where 
 
      ∴  𝑝1
∗ = 𝑎1 + 𝑑2 + (𝑐1 + 𝑐3)𝑑1̅̅ ̅ + 𝑑 (21) 
          𝑝2
∗ = (𝑎1 + 𝑑2 + 𝑐1𝑑1̅̅ ̅)(𝑑 + 𝑐3𝑑1̅̅ ̅) − 2𝑎1𝑎4 (22) 
 
The value of 𝑝1
∗ is always positive [15, 16, 22]. The value 
of 𝑝2
∗ can be negative or positive. According to the 
Routh-Hurwitz stability criteria the fixed point (0,0,
𝑘
𝑑1
) 
will stable if 𝑝1
∗ > 0 and 𝑝2
∗ > 0. Thus, the necessary 
condition for the tumor growth is given by Eq. (23). 
 
      𝑑 <
−(𝑐1 + 𝑐3)𝑑1̅̅ ̅ + 2𝑎1𝑎4
𝑑2 + 𝑎1
 (23) 
 
 
 
 
Figure 4 Stability region for the case with the presence of 
immune response when 𝑎4 = 0.8, 𝑐1 = 𝑐3 = 0.9, 𝑑2 = 0.11 and 
𝑑1̅̅ ̅ = 0.1241 
 
 
 
Figure 5 Stability region for both cases 
 
 
 
Figure 6 Numerical example for stable fixed point (0,0,
𝑘
𝑑1
) 
when 𝑎1 = 1 and 𝑑 = 1.3 with initial condition 𝑇𝐼 = 1.3, 𝑇𝑀 = 1.2 
and 𝐼 = 0.9 
 
IV 
III 
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Figure 7 Numerical example for unstable fixed point (0,0,
𝑘
𝑑1
) 
when 𝑎1 = 1 and 𝑑 = 1.15 with initial condition 𝑇𝐼 = 1.3, 𝑇𝑀 =
1.2 and 𝐼 = 0.9 
 
 
From Figure 4, the region for tumor growth, where 
(0,0,
𝑘
𝑑1
) is unstable is given by III and the region for 
tumor decay where (0,0,
𝑘
𝑑1
) is stable is given by the 
complement IV. It can be seen in Figure 5 that the 
region of tumor growth without immune response for 
system (11) is larger than the region of tumor growth 
with the presence of immune response for system (17). 
Thus, system (17) is more stable compared to system 
(11). Various values were chosen from different regions 
to observe the solution of the system as presented in 
Figure 6 and Figure 7. 
 
3.3 Tumor System with Single Drug 
 
Now, consider the effect of single drug to the system 
 
     
𝑑𝑇𝐼
𝑑𝑡
= 2𝑎4𝑇𝑀 − (𝑐1𝐼 + 𝑑2)𝑇𝐼 − 𝑎1𝑇𝐼 
(24) 
   
𝑑𝑇𝑀
𝑑𝑡
= 𝑎1𝑇𝐼 − 𝑑3𝑇𝑀 − 𝑎4𝑇𝑀 − 𝑐3𝑇𝑀𝐼
− 𝑘1(1 − 𝑒
−𝑘2𝑢)𝑇𝑀 
      
𝑑𝐼
𝑑𝑡
= 𝑘 +
𝜌𝐼(𝑇𝐼 + 𝑇𝑀)
𝑛
𝛼 + (𝑇𝐼 + 𝑇𝑀)𝑛
− 𝑐2𝐼𝑇𝐼 − 𝑐4𝑇𝑀𝐼 − 𝑑1𝐼
− 𝑘3(1 − 𝑒
−𝑘4𝑢)𝐼 
      
𝑑𝑢
𝑑𝑡
= −𝛾𝑢 
 
One of the tumor free point for this system is 
(𝑇𝐼 , 𝑇𝑀, 𝐼, 𝑢) = (0,0,
𝑘
𝑑1
, 0) with zero tumor and drug level. 
This represents a tumor and drug free condition and 
serves as the base for reference. The factorization form 
of the auxiliary equation at this steady state yields Eq. 
(24) 
 
(−𝛾 − 𝜆)(−𝑑1 − 𝜆)[(−𝑐1𝑑1̅̅ ̅ − 𝑑2 − 𝑎1 − 𝜆)(−𝑑
− 𝑐3𝑑1̅̅ ̅ − 𝜆) − 2𝑎1𝑎4] = 0 
(25) 
 
where 𝑑1̅̅ ̅ =
𝑘
𝑑1
. Clearly, two of the eigenvalues are 𝜆 =
−𝛾 and 𝜆 = −𝑑1. The other eigenvalues are given as 
the solutions to the auxiliary equation 
 
𝜆2 + [𝑎1 + 𝑑2 + (𝑐1 + 𝑐3)𝑑1̅̅ ̅ + 𝑑]𝜆
+ (𝑎1 + 𝑑2 + 𝑐1𝑑1̅̅ ̅)(𝑑
+ 𝑐3𝑑1̅̅ ̅) − 2𝑎1𝑎4 = 0 
(26) 
                                               𝜆2 + 𝑝1
∗∗𝜆 + 𝑝2
∗∗ = 0 (27) 
 
where 
 
 
    ∴  𝑝1
∗∗ = 𝑎1 + 𝑑2 + (𝑐1 + 𝑐3)𝑑1̅̅ ̅ + 𝑑 (28) 
         𝑝2
∗∗ = (𝑎1 + 𝑑2 + 𝑐1𝑑1̅̅ ̅)(𝑑 + 𝑐3𝑑1̅̅ ̅) − 2𝑎1𝑎4 (29) 
 
The value of 𝑝1
∗∗ is always positive [15, 16, 22]. The value 
of 𝑝2
∗∗ can be negative or positive. According to the 
Routh-Hurwitz stability criteria the fixed point (0,0,
𝑘
𝑑1
, 0) 
will be stable if 𝑝1
∗∗ > 0 and 𝑝2
∗∗ > 0. Thus the necessary 
condition for the tumor growth is given by Eq. (30) 
 
                        𝑑 <
−(𝑐1 + 𝑐3)𝑑1̅̅ ̅ + 2𝑎1𝑎4
𝑑2 + 𝑎1
 (30) 
 
Notice that Eq. (30) is the same as Eq. (23). Hence, it 
has the same stability region as the previous system. It 
can be concluded that this system has the same 
stability characteristics as the tumor system without 
the application of drug. 
To observe the effect of the drug towards the 
tumor population, numerical calculations were 
carried out, with results plotted using three different 
amounts of drug or initial value, 𝑢0 which are 𝑢0 =
0.05, 𝑢0 = 0.1, and  𝑢0 = 0.15. These values are chosen 
from the range 0 ≤ 𝑢0 ≤ 0.15 founded in [23]. 
 
 
 
Figure 8 Numerical example for tumor system with the 
presence of immune response and drug when 𝑎1 = 1 and 𝑑 =
1.15 with initial condition 𝑇𝐼 = 1.3, 𝑇𝑀 = 1.2, 𝐼 = 0.9 and 𝑢 = 0.05 
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Figure 9 Numerical example for tumor system with the 
presence of immune response and drug when 𝑎1 = 1 and 𝑑 =
1.15 with initial condition 𝑇𝐼 = 1.3, 𝑇𝑀 = 1.2, 𝐼 = 0.9 and 𝑢 = 0.1 
 
 
 
Figure 10 Numerical example for tumor system with the 
presence of immune response and drug when 𝑎1 = 1 and 𝑑 =
1.15 with initial condition 𝑇𝐼 = 1.3, 𝑇𝑀 = 1.2, 𝐼 = 0.9 and 𝑢 = 0.15 
 
 
In Figure 8, the graph of the solution shows that the 
tumor population is growing when the amount of drug 
is 𝑢0 = 0.05. Next, the initial amount of drug is increased 
to 𝑢0 = 0.1, and the graph of the solution is shown in 
Figure 9. 
From Figure 9, the tumor population is still growing 
even when the amount of drug have been increased. 
According to [23], the upper limit of reasonable drug 
is 0.15. By taking this highest amount of drug as a final 
selection, the graph of solution is then produced in 
Figure 10 to see whether the population of tumor grow 
or decay as time progresses. 
It is obvious that the population of tumor still does 
not display any change with time. It can be 
concluded that the system maintains stability even 
though the maximum amount of drug have been 
delivered. However, the numerical values explain the 
differences between these figures.  
These value were presented in the Table 1 while 
another comparison of numerical values between 
tumor system with immune response and drug system 
with 𝑢0 = 0.15 have been tabulated in Table 2. 
 
Table 1 Comparison of numerical values for tumor on each       
phase with respect to different amount of drug 
 
t 
𝒖𝟎 = 𝟎.𝟎𝟓 𝒖𝟎 = 𝟎. 𝟏 𝒖𝟎 = 𝟎. 𝟏𝟓 
𝑻𝑰 𝑻𝑴 𝑻𝑰 𝑻𝑴 𝑻𝑰 𝑻𝑴 
10 0.2185 0.1700 0.2173 0.1691 0.2162 0.1683 
20 0.2562 0.1994 0.2550 0.1984 0.2539 0.1976 
30 0.3282 0.2554 0.3269 0.2543 0.3255 0.2533 
40 0.4131 0.3214 0.4115 0.3202 0.4100 0.3190 
50 0.5147 0.4005 0.5127 0.3990 0.5108 0.3975 
60 0.6511 0.5067 0.6483 0.5045 0.6456 0.5024 
 
Table 2 Comparison of numerical values for tumor on each 
phase for tumor system in the presence of immune response 
and tumor system with the presence of immune response 
and drug 
 
t 
without drug, 
immune is present 
with drug 𝒖𝟎 = 𝟎. 𝟏𝟓, 
immune is present 
𝑻𝑰 𝑻𝑴 𝑻𝑰 𝑻𝑴 
10 0.2197 0.1710 0.2162 0.1683 
20 0.2574 0.2003 0.2539 0.1976 
30 0.3296 0.2565 0.3255 0.2533 
40 0.4147 0.3277 0.4100 0.3190 
50 0.5168 0.4021 0.5108 0.3975 
60 0.6541 0.5090 0.6456 0.5024 
 
 
From Table 2 above, the population of tumor cells 
at interphase and metaphase decrease at 1.27% and 
1.53% respectively. This shows that the system with 
implementation of drug provide a better way for 
treatment in patients.  
 
 
4.0  CONCLUSION 
 
This research considers three cases which are tumor 
system without immune response, tumor system with 
the presence of immune response and tumor system 
with single drug. Same procedure of stability analysis 
were done on each cases. For tumor system without 
immune response, the only steady state obtained is at 
origin. In this steady state, two regions of stability can 
be produced by fixing all parameters except for 
parameter 𝑎1 and 𝑑. The regions are tumor growth 
region and tumor decay region, denoted by I and II 
respectively. By choosing a specific pair specific pair 
of value for parameter a1 and d in each region, the 
system is solved numerically using Fourth Order Runge 
Kutta Method. The result shows the population of 
tumor at interphase and metaphase increases when 
the values of parameter 𝑎1 and 𝑑 are fixed at the 
tumor growth region I. While the population of tumor 
decreases when the value of parameter a1 and d are 
fixed at the tumor decay region II. This implies that 
different values of parameter 𝑎1 and 𝑑 affect the 
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stability of the system. It is important to maintain the 
value of 𝑎1 and 𝑑 so the system will maintain at tumor 
decay region.  
Previous models were not realistic since the system 
did not include immune response. By adding the 
immune response, the model now involves the 
competition of three populations. This system has 
more than one steady states. However, this study only 
analyse the steady state in which tumor populations 
on both phases are zero. The stability region 𝑎1 and 𝑑 
again is produced and then compared to the 
previous systems. From the stability region, the curve 
built in this system shows reduction in the tumor growth 
region compared to the previous system. It shows that 
this system is more stable since immune system 
naturally fights infections, including tumor. With the 
presence of immune system, numerical examples 
show that the population of tumor is decreased 
compared to the previous system. It can also be seen 
that the immune population maintain at a constant 
rate as time progresses. However, drug is needed to 
fight tumor since tumor growth persists even with the 
presence of immune response. 
The drug effect is added into the tumor system with 
immune response. There exists another steady states 
but this research only looks at the steady state with 
zero tumor population and drug with positive immune 
level. From the stability analysis, the steady states have 
the same stability characteristics as tumor system with 
immune response. This means that if a certain amount 
of drug is given to the patient, this system will exhibit 
the same behaviour as the previous system. However, 
the population of tumor is decreased by 1.27% at 
interphase and 1.53% at metaphase. This implies that 
combination of immune and drug provide a better 
way to kill tumor cells. 
Several recommendations are presented as 
guides for future study. These include the effect of 
delay in the cell cycle may improve our findings. It 
seems more realistic since the tumor are trapped for a 
certain time in the mitosis for immune cells to kill it after 
being affected by drug. Besides, including quiescent 
phase could help us to understand either this phase 
will contribute or delay the progression of the 
population of tumor. A more detailed modelling 
involving immune systems also may provide many 
ideas. One such possibility is to include more types of 
immune cells to the model for analysis. 
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